Ligand Pharmaceuticals Rises After Upsized Convertible Notes Pricing and Buyback Plan

Ligand Pharmaceuticals (LGND) is up 5.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor relief after Ligand priced an upsized $625 million convertible notes deal with 0.0% interest, a 27.5% conversion premium, and a concurrent $60 million share repurchase. The structure appears to have eased dilution concerns while giving the company added flexibility to fund growth initiatives, including its pending XOMA Royalty acquisition.

Details:

Ligand priced $625 million of convertible senior notes due 2031, up from the $550 million size it initially proposed a day earlier.

The company said the notes carry no regular interest, and the initial conversion price is about $334.27 per share, well above the prior closing stock price.

Ligand plans to use about $60 million of the proceeds to repurchase roughly 228,859 shares at $262.17, a step designed to offset part of the potential dilution from the financing.

The remaining proceeds are intended for general corporate purposes, with the company highlighting its previously announced agreement to acquire XOMA Royalty as a key use of capital.

Sources:

Ligand Pharmaceuticals investor relations, SEC, StockTitan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LGND Insider Trading Activity

$LGND insiders have traded $LGND stock on the open market 83 times in the past 6 months. Of those trades, 0 have been purchases and 83 have been sales.

Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:

ANDREW REARDON (CLO & Secretary) has made 0 purchases and 31 sales selling 20,000 shares for an estimated $4,329,865.
OCTAVIO ESPINOZA (Chief Financial Officer) has made 0 purchases and 12 sales selling 16,480 shares for an estimated $3,450,647.
JASON HAAS has made 0 purchases and 2 sales selling 6,461 shares for an estimated $1,651,320.
JOHN L LAMATTINA has made 0 purchases and 5 sales selling 6,752 shares for an estimated $1,585,616.
JASON ARYEH has made 0 purchases and 2 sales selling 5,000 shares for an estimated $1,250,000.
STEPHEN L SABBA has made 0 purchases and 3 sales selling 5,179 shares for an estimated $1,162,553.
JOHN W KOZARICH has made 0 purchases and 28 sales selling 4,369 shares for an estimated $931,174.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive LGND Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$LGND Hedge Fund Activity

We have seen 185 institutional investors add shares of $LGND stock to their portfolio, and 181 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MACQUARIE GROUP LTD removed 751,788 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $142,140,557
ACUITAS INVESTMENTS, LLC removed 402,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $76,099,540
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 150,696 shares (-41.4%) from their portfolio in Q1 2026, for an estimated $30,086,456
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 146,265 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $29,201,807
INVESCO LTD. added 138,169 shares (+36.5%) to their portfolio in Q4 2025, for an estimated $26,123,612
JACOBS LEVY EQUITY MANAGEMENT, INC removed 106,225 shares (-83.8%) from their portfolio in Q1 2026, for an estimated $21,207,821
NEXT CENTURY GROWTH INVESTORS LLC added 95,876 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,141,643

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LGND Congressional Stock Trading

Members of Congress have traded $LGND stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $LGND stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 4 purchases worth up to $60,000 on 05/29, 03/03, 01/15, 01/05 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LGND Price Targets

Multiple analysts have issued price targets for $LGND recently. We have seen 5 analysts offer price targets for $LGND in the last 6 months, with a median target of $277.0.

Here are some recent targets:

Douglas Miehm from RBC Capital set a target price of $262.0 on 05/08/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $289.0 on 04/30/2026
Yigal Nochomovitz from Citigroup set a target price of $282.0 on 04/15/2026
Jason Zemansky from B of A Securities set a target price of $244.0 on 03/11/2026
Trevor Allred from Oppenheimer set a target price of $277.0 on 02/27/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.